Related Experiment Video

Updated: May 23, 2026

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

A cardiologist's quick guide to lupus

Jennifer Taylor

    European Heart Journal
    |March 23, 2012
    PubMed

    Insights

    Accelerated atherosclerosis is a significant issue for patients with lupus. This condition involves the rapid buildup of plaque in arteries, increasing cardiovascular risk.

    Area of Science:

    • Cardiovascular Medicine
    • Rheumatology
    • Immunology

    Background:

    • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease.
    • Patients with SLE exhibit a markedly increased risk of premature cardiovascular disease.
    • Accelerated atherosclerosis is a primary driver of this heightened cardiovascular morbidity and mortality in lupus.

    Purpose of the Study:

    • To investigate the mechanisms underlying accelerated atherosclerosis in patients with systemic lupus erythematosus.
    • To identify key risk factors and biomarkers associated with early atherosclerotic development in SLE.
    • To explore potential therapeutic targets for mitigating cardiovascular complications in lupus.

    Main Methods:

    • Systematic review of epidemiological studies and clinical trials.
    • Analysis of inflammatory pathways and immune cell involvement in lupus-associated atherosclerosis.
    • Evaluation of traditional and non-traditional cardiovascular risk factors in SLE cohorts.

    Main Results:

    • Inflammation, immune dysregulation, and endothelial dysfunction are central to accelerated atherosclerosis in SLE.
    • Specific autoantibodies and elevated inflammatory markers are associated with increased atherosclerotic burden.
    • Traditional risk factors, when present, exacerbate cardiovascular risk in lupus patients.

    Conclusions:

    • Accelerated atherosclerosis poses a major threat to the long-term health of individuals with systemic lupus erythematosus.
    • Comprehensive cardiovascular risk management, including aggressive control of inflammation and immune activity, is crucial.
    • Further research into targeted therapies is warranted to prevent and treat atherosclerosis in this vulnerable population.

    More Related Videos

    The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice12:04

    The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

    Published on: November 1, 2015

    Related Concept Videos

    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    Cardiomyopathy I: Introduction and Classification01:25

    Cardiomyopathy I: Introduction and Classification

    Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
    Rheumatic Heart Disease I: Introduction01:23

    Rheumatic Heart Disease I: Introduction

    Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
    Pericarditis I: Introduction01:22

    Pericarditis I: Introduction

    Pericarditis is defined as the inflammation of the pericardium, the thin, sac-like membrane surrounding the heart. This condition can cause significant chest pain and other symptoms, often necessitating medical intervention. The pericardium has two layers: the inner visceral layer and the outer parietal layer, separated by a small amount of fluid that reduces friction during heartbeats.Types of PericarditisPericarditis can be classified into several types based on the duration and nature of the...
    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    Myocarditis IV: Nursing Management01:22

    Myocarditis IV: Nursing Management

    Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...